Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardiomyopathy

Şeneş, Mehmet; Erbay, Ali Rıza; Yılmaz, Fatma Meriç; Topkaya, B Ç; Zengi, Oğuzhan; Doğan, Murat; Yücel, Doğan

doi:10.1515/cclm.2008.061

Cited by 21 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cardiomyopathies are a number of debilitating conditions responsible for poor quality of life and high risk of mortality. Both in vitro and animal studies suggest a link between cardiomyopathies and oxidative stress [120]. CoQ 10 deficiency appears to be frequent in people with dilated cardiomyopathy, and its supplementation may be able to restore plasmatic and myocardial levels [121].…”

Section: Coq 10 and Nonischemic Cardiomyopathiesmentioning

confidence: 99%

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ10) is a ubiquitous factor present in cell membranes and mitochondria, both in its reduced (ubiquinol) and oxidized (ubiquinone) forms. Its levels are high in organs with high metabolism such as the heart, kidneys, and liver because it acts as an energy transfer molecule but could be reduced by aging, genetic factors, drugs (e.g., statins), cardiovascular (CV) diseases, degenerative muscle disorders, and neurodegenerative diseases. As CoQ10 is endowed with significant antioxidant and anti-inflammatory features, useful to prevent free radical-induced damage and inflammatory signaling pathway activation, its depletion results in exacerbation of inflammatory processes. Therefore, exogenous CoQ10 supplementation might be useful as an adjuvant in the treatment of cardiovascular diseases such as heart failure, atrial fibrillation, and myocardial infarction and in associated risk factors such as hypertension, insulin resistance, dyslipidemias, and obesity. This review aims to summarize the current evidences on the use of CoQ10 supplementation as a therapeutic approach in cardiovascular diseases through the analysis of its clinical impact on patients’ health and quality of life. A substantial reduction of inflammatory and oxidative stress markers has been observed in several randomized clinical trials (RCTs) focused on several of the abovementioned diseases, even if more RCTs, involving a larger number of patients, will be necessary to strengthen these interesting findings.

show abstract

Section: Coq 10 and Nonischemic Cardiomyopathiesmentioning

confidence: 99%

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Oxidative stress, defined as “an imbalance between oxidants and antioxidants in favor of the oxidants, leading to a disruption of redox signaling and control and/or molecular damage” [ 4 ], is present in human cardiovascular diseases (CVD) and heart failure (HF) [ 5 , 6 ]. Low levels of plasma and myocardial CoQ 10 have been found in human CVD [ 7 , 8 , 9 , 10 ]. Due to the known fact of CoQ 10 deficiency in people with CVD, the role of CoQ 10 in energy production, and its antioxidant potential, supplemental CoQ 10 has long been studied as an adjunctive treatment in human HF patients [ 11 , 12 , 13 , 14 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Coenzyme Q10 Supplementation on Oxidative Stress Markers, Inflammatory Markers, Lymphocyte Subpopulations, and Clinical Status in Dogs with Myxomatous Mitral Valve Disease

et al. 2022

View full text Add to dashboard Cite

Scarce data exist on the effects of coenzyme Q10 (CoQ10) supplementation in dogs with myxomatous mitral valve disease (MMVD). The purpose of this study was to investigate the effect of CoQ10 supplementation on oxidative stress markers (glutathione peroxidase, F2-isoprostanes), markers of inflammation (tumor necrosis factor-α, TNF soluble receptor II, leucocytes, and their subtypes), lymphocyte subpopulations (T helper and cytotoxic T lymphocytes, including activated T lymphocytes, and B lymphocytes), and echocardiographic and clinical parameters in dogs with MMVD. In this randomized, controlled, double-blind, longitudinal study, 43 MMVD dogs in stages ACVIM (American College of Veterinary Internal Medicine classification) B2 and ACVIM C and D (congestive heart failure (CHF)) received water-soluble coenzyme Q10 (100 mg twice daily) or placebo for 3 months, and 12 non-supplemented healthy dogs served as controls. All parameters were measured before and after supplementation in MMVD dogs and once in healthy dogs. CoQ10 supplementation had a positive impact on neutrophil percentage, lymphocyte percentage, and lymphocyte concentration in our cohort of dogs with CHF (ACVIM C and D). Conclusion: CoQ10 as an oral supplement may have benefits in terms of decreasing inflammation in dogs with MMVD and CHF.

show abstract

“…Cardiomyopathy is a debilitating condition, which is associated with a high mortality and poor quality of life. There is extensive evidence from in vitro and animal studies that it is linked to increased oxidative stress [79].…”

Section: Cardiomyopathymentioning

confidence: 99%

Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem

Zozina

Covanţev

Goroshko

et al. 2018

CCR

131

View full text Add to dashboard Cite

The burden of cardiovascular and metabolic diseases is increasing with every year. Although the management of these conditions has improved greatly over the years, it is still far from perfect. With all of this in mind, there is a need for new methods of prophylaxis and treatment. Coenzyme Q10 (CoQ10) is an essential compound of the human body. There is growing evidence that CoQ10 is tightly linked to cardiometabolic disorders. Its supplementation can be useful in a variety of chronic and acute disorders. This review analyses the role of CoQ10 in hypertension, ischemic heart disease, myocardial infarction, heart failure, viral myocarditis, cardiomyopathies, cardiac toxicity, dyslipidemia, obesity, type 2 diabetes mellitus, metabolic syndrome, cardiac procedures and resuscitation.

show abstract

Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardiomyopathy

Cited by 21 publications

References 29 publications

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

Effects of Coenzyme Q10 Supplementation on Oxidative Stress Markers, Inflammatory Markers, Lymphocyte Subpopulations, and Clinical Status in Dogs with Myxomatous Mitral Valve Disease

Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem

Contact Info

Product

Resources

About